(Total Views: 786)
Posted On: 10/14/2020 2:26:02 PM
Post# of 154977
From the august 04 PR
"The DSMC reviewed compiled safety data from 149 subjects enrolled in the CD12 trial. The DSMC did not raise any concerns regarding safety and recommended that the trial continue."
however in the ASM presentation, NP had 100 subjects for CD12 safety review. That seems like huge discrepancy. 149 for DSMC with no concerns makes the interim review outcome almost certainly positive. the question is how big of a positive it will be.
"The DSMC reviewed compiled safety data from 149 subjects enrolled in the CD12 trial. The DSMC did not raise any concerns regarding safety and recommended that the trial continue."
however in the ASM presentation, NP had 100 subjects for CD12 safety review. That seems like huge discrepancy. 149 for DSMC with no concerns makes the interim review outcome almost certainly positive. the question is how big of a positive it will be.
(1)
(0)
